Vera Health raises $28.5M Series A as clinical AI tool hits 800,000 users
What's the deal? Vera HealthDealroom has a profile for this one. Try Dealroom → has raised a $28.5 million Series A led by Threshold Ventures, with participation from Optum VenturesDealroom has a profile for this one. Try Dealroom →, MantisDealroom has a profile for this one. Try Dealroom → VC, and SV Angel. The startup runs a clinical AI search engine that helps physicians find and evaluate medical evidence, linking each claim to its source and colour-coding the strength of the research behind it.
By the numbers: The round sits in the 81st percentile for amount, placing it among the larger raises in its cohort. Existing backers Y Combinator and Gradient increased their stakes, lifting Vera's total funding to $32 million.
Why now? Vera says its tool has grown from a few thousand users to more than 800,000 clinicians across 190 countries in about a year, with a team of just 12. In Spain and Italy, roughly one in four physicians use it; in France, about one in seven.
What's the endgame? The platform searches more than 60 million scientific publications, clinical guidelines, and drug labels before producing an answer, surfacing research limitations so physicians can judge how much weight findings deserve. Co-founded by Maxime Allouch and Taieb Bennani, it was first built for the founders' fathers, both physicians.
Where it's heading: Vera is funding international growth with a local-first approach that tailors answers to national guidelines and language — French and European guidance for a doctor in Lyon, for example, versus a different framework in Chicago. Growth has run largely on physician referrals.
"We built Vera with clinicians, and clinicians did the rest," Bennani said. "They check the sources, test every answer against what they know, and drop a tool the moment it lets them down."
What could go wrong? The user figures are company-reported and do not, on their own, show accuracy, sustained use, or clinical impact. Vera also faces a crowding field: OpenEvidence has drawn major funding and broad physician adoption, while established reference platforms remain strong alternatives.
The signal: Investor appetite for clinical-AI search is intensifying, and Vera's pitch — evidence-first answers over confident AI guesses — is winning capital on the strength of fast, referral-driven uptake. Whether that translates into durable clinical value is the open question.
Read more: Tech.eu
Image credit: Vera Health
